{"id":"abiraterone-acetate-suspension-formulation-1","safety":{"commonSideEffects":[{"rate":"42%","effect":"Fatigue"},{"rate":"37%","effect":"Hypertension"},{"rate":"35%","effect":"Diarrhea"},{"rate":"34%","effect":"Nausea"},{"rate":"32%","effect":"Muscle spasm"}]},"_chembl":{"chemblId":"CHEMBL271227","moleculeType":"Small molecule","molecularWeight":"391.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abiraterone acetate is a potent inhibitor of the enzyme CYP17, which is involved in the biosynthesis of androgens. By inhibiting CYP17, abiraterone acetate reduces the production of androgens, such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells.","oneSentence":"Androgen receptor inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:50.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT04887506","phase":"PHASE3","title":"TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Tavanta Therapeutics","startDate":"2021-05-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer","enrollment":107},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT01362764","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2011-05","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Abiraterone acetate suspension Formulation 1","genericName":"Abiraterone acetate suspension Formulation 1","companyName":"Cougar Biotechnology, Inc.","companyId":"cougar-biotechnology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androgen receptor inhibitor Used for Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}